Efficacy of Panitumumab Plus FOLFIRI Versus FOLFIRI Alone in Patients With Wild-Type (WT) KRas Metastatic Colorectal Cancer (mCRC) Treated With Prior Oxaliplatin or Bevacizumab Regimens: Results From 20050181

被引：1

作者：

Price, T. ^{[1
]}

Peeters, M. ^{[2
]}

Strickland, A. ^{[3
]}

Ciuleanu, T. E. ^{[4
]}

Scheithauer, W. ^{[5
]}

O'Reilly, S. ^{[6
]}

Keane, M. ^{[7
]}

Spigel, D. ^{[8
,9
]}

Tian, Y. ^{[10
]}

Kartik, K. ^{[11
]}

机构：

[1] Queen Elizabeth Hosp, Haematol Med Oncol Unit, Woodville, SA 5011, Australia

[2] Antwerp Univ Hosp, Edegem, Belgium

[3] Monash Med Ctr, E Bentleigh, Australia

[4] Inst Oncol I Chiricuta, Cluj Napoca, Romania

[5] Med Univ Vienna, Vienna, Austria

[6] Cork Mercy S Infirm Victoria Univ Hosp, Cork, Ireland

[7] W Ireland Canc Ctr, Galway, Ireland

[8] Sarah Cannon Res Inst, Nashville, TN USA

[9] Tennessee Oncol PLLC, Med Oncol, Nashville, TN USA

[10] Amgen Inc, Biostat, Thousand Oaks, CA 91320 USA

[11] Amgen Inc, Clin Sci, Thousand Oaks, CA 91320 USA

来源：

关键词：

D O I：

10.1016/S0959-8049(11)71777-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S431 / S432

页数：2